Overview

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the best dose of clofarabine and fludarabine that can be given with busulfan followed by an allogeneic blood stem cell transplant. Researchers will study whether this combination can help to control the disease, and look at the safety of this combination. Researchers also want to find out if combining busulfan with clofarabine alone or combining busulfan with both fludarabine and clofarabine will improve the treatment, compared with the previous standard method using busulfan and fludarabine alone.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Antilymphocyte Serum
Busulfan
Clofarabine
Fludarabine
Fludarabine phosphate
Lenograstim
Sargramostim
Thymoglobulin
Vidarabine